

World Journal of *Gastroenterology*

World J Gastroenterol 2017 September 14; 23(34): 6197-6370



**EDITORIAL**

- 6197** Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy

Papamichael K, Cheifetz AS

MINIREVIEWS

- 6201** Evidences supporting the vascular etiology of post-double balloon enteroscopy pancreatitis: Study in porcine model

Latorre R, López-Albors O, Soria F, Morcillo E, Esteban P, Pérez-Cuadrado-Robles E, Pérez-Cuadrado-Martínez E

ORIGINAL ARTICLE**Basic Study**

- 6212** Circulating inflammatory factors associated with worse long-term prognosis in colorectal cancer

Olsen RS, Nijm J, Andersson RE, Dimberg J, Wågsäter D

- 6220** Moxibustion eases chronic inflammatory visceral pain through regulating MEK, ERK and CREB in rats

Li ZY, Huang Y, Yang YT, Zhang D, Zhao Y, Hong J, Liu J, Wu LJ, Zhang CH, Wu HG, Zhang J, Ma XP

- 6231** Changes of Ghrelin/GOAT axis and mTOR pathway in the hypothalamus after sleeve gastrectomy in obese type-2 diabetes rats

Wang Q, Tang W, Rao WS, Song X, Shan CX, Zhang W

- 6242** Dihydromyricetin-mediated inhibition of the Notch1 pathway induces apoptosis in QGY7701 and HepG2 hepatoma cells

Lu CJ, He YF, Yuan WZ, Xiang LJ, Zhang J, Liang YR, Duan J, He YH, Li MY

- 6252** Curcumin inhibits hepatitis B virus infection by down-regulating cccDNA-bound histone acetylation

Wei ZQ, Zhang YH, Ke CZ, Chen HX, Ren P, He YL, Hu P, Ma DQ, Luo J, Meng ZJ

Retrospective Cohort Study

- 6261** Systemic immune-inflammation index for predicting prognosis of colorectal cancer

Chen JH, Zhai ET, Yuan YJ, Wu KM, Xu JB, Peng JJ, Chen CQ, He YL, Cai SR

Retrospective Study

- 6273** Predictive factors for the failure of endoscopic stent-in-stent self-expandable metallic stent placement to treat malignant hilar biliary obstruction

Sugimoto M, Takagi T, Suzuki R, Konno N, Asama H, Watanabe K, Nakamura J, Kikuchi H, Waragai Y, Takasumi M, Sato Y, Hikichi T, Ohira H

- 6281 Assessment of colon polyp morphology: Is education effective?

Kim JH, Nam KS, Kwon HJ, Choi YJ, Jung K, Kim SE, Moon W, Park MI, Park SJ

- 6287 Body mass index does not affect the survival of pancreatic cancer patients

Jiang QL, Wang CF, Tian YT, Huang H, Zhang SS, Zhao DB, Ma J, Yuan W, Sun YM, Che X, Zhang JW, Chu YM, Zhang YW, Chen YT

Observational Study

- 6294 Access to biologicals in Crohn's disease in ten European countries

Péntek M, Lakatos PL, Oorsprong T, Gulácsi L, Pavlova M, Groot W, Rencz F, Brodsky V, Baji P; Crohn's Disease Research Group

- 6306 Temporal trends in the misdiagnosis rates between Crohn's disease and intestinal tuberculosis

Seo H, Lee S, So H, Kim D, Kim SO, Soh JS, Bae JH, Lee SH, Hwang SW, Park SH, Yang DH, Kim KJ, Byeon JS, Myung SJ, Yang SK, Ye BD

- 6315 Detection of metastatic cancer cells in mesentery of colorectal cancer patients

Luo XL, Xie DX, Wu JX, Wu AD, Ge ZQ, Li HJ, Hu JB, Cao ZX, Gong JP

- 6321 Natural history of covert hepatic encephalopathy: An observational study of 366 cirrhotic patients

Wang AJ, Peng AP, Li BM, Gan N, Pei L, Zheng XL, Hong JB, Xiao HY, Zhong JW, Zhu X

Randomized Controlled Trial

- 6330 Circular RNA hsa_circ_0000745 may serve as a diagnostic marker for gastric cancer

Huang M, He Yr, Liang LC, Huang Q, Zhu ZQ

- 6339 P2Y1R is involved in visceral hypersensitivity in rats with experimental irritable bowel syndrome

Wu J, Cheng Y, Zhang R, Liu D, Luo YM, Chen KL, Ren S, Zhang J

- 6350 Randomized controlled trial of uncut Roux-en-Y vs Billroth II reconstruction after distal gastrectomy for gastric cancer: Which technique is better for avoiding biliary reflux and gastritis?

Yang D, He L, Tong WH, Jia ZF, Su TR, Wang Q

Randomized Clinical Trial

- 6357 Drainage fluid and serum amylase levels accurately predict development of postoperative pancreatic fistula

Jin S, Shi XJ, Wang SY, Zhang P, Lv GY, Du XH, Wang GY

CASE REPORT

- 6365 Interventional endoscopic ultrasound for a symptomatic pseudocyst secondary to gastric heterotopic pancreas

Jin HB, Lu L, Yang JF, Lou QF, Yang J, Shen HZ, Tang XW, Zhang XF

ABOUT COVER

Editorial board member of *World Journal of Gastroenterology*, Gabriele Grassi, MD, PhD, Associate Professor, Department of Life Sciences, University Hospital of Cattinara, 34149 Trieste, Italy

AIMS AND SCOPE

World Journal of Gastroenterology (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7th, 14th, 21st, and 28th each month. The *WJG* Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

INDEXING/ABSTRACTING

World Journal of Gastroenterology (*WJG*) is now indexed in Current Contents[®]/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch[®]), Journal Citation Reports[®], Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2017 edition of Journal Citation Reports[®] cites the 2016 impact factor for *WJG* as 3.365 (5-year impact factor: 3.176), ranking *WJG* as 29th among 79 journals in gastroenterology and hepatology (quartile in category Q2).

FLYLEAF

I-IX Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*
Responsible Electronic Editor: *Fen-Fen Zhang*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Ke Chen*
Proofing Editorial Office Director: *Jin-Lei Wang*

NAME OF JOURNAL
World Journal of Gastroenterology

ISSN
ISSN 1007-9327 (print)
ISSN 2219-2840 (online)

LAUNCH DATE
October 1, 1995

FREQUENCY
Weekly

EDITORS-IN-CHIEF

Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

Stephen C Strom, PhD, Professor, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

EDITORIAL BOARD MEMBERS

All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

EDITORIAL OFFICE

Jin-Lei Wang, Director
Yuan Qi, Vice Director
Ze-Mao Gong, Vice Director
World Journal of Gastroenterology
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLISHER

Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>

<http://www.wjgnet.com>

PUBLICATION DATE
September 14, 2017

COPYRIGHT

© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT

All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS

Full instructions are available online at <http://www.wjgnet.com/bpg/getinfo/204>

ONLINE SUBMISSION
<http://www.f6publishing.com>

Basic Study

Curcumin inhibits hepatitis B virus infection by down-regulating cccDNA-bound histone acetylation

Zhi-Qiang Wei, Yong-Hong Zhang, Chang-Zheng Ke, Hong-Xia Chen, Pan Ren, Yu-Lin He, Pei Hu, De-Qiang Ma, Jie Luo, Zhong-Ji Meng

Zhi-Qiang Wei, Hong-Xia Chen, Yu-Lin He, Zhong-Ji Meng, Institute of Biomedical Research, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, Hubei Province, China

Zhi-Qiang Wei, Chang-Zheng Ke, De-Qiang Ma, Zhong-Ji Meng, Department of Infectious Diseases, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, Hubei Province, China

Yong-Hong Zhang, Institute of Wudang Chinese Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, Hubei Province, China

Pan Ren, Hubei University of Chinese Medicine, Wuhan 430000, Hubei Province, China

Pei Hu, Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan 430000, Hubei Province, China

Jie Luo, Center for Evidence-Based Medicine and Clinical Research, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, Hubei Province, China

ORCID number: Zhi-Qiang Wei (0000-0002-6067-589X); Yong-Hong Zhang (0000-0002-5741-9406); Chang-Zheng Ke (0000-0002-9766-7420); Hong-Xia Chen (0000-0003-2331-0880); Pan Ren (0000-0001-5445-433X); Yu-Lin He (0000-0002-4728-523X); Pei Hu (0000-0003-0116-7737); De-Qiang Ma (0000-0003-3657-7576); Jie Luo (0000-0002-6043-472X); Zhong-Ji Meng (0000-0003-0401-535X).

Author contributions: Wei ZQ, Zhang YH and Ke CZ performed the experiments; Meng ZJ and Luo J designed and coordinated the research; Cheng HX and Ma DQ analyzed the data; Wei ZQ and Meng ZJ wrote the paper; Ren P and Hu P reviewed and edited the manuscript; all authors read and approved the manuscript.

Supported by National Natural Science Foundation of China, No. 81541140; Natural Science Foundation of Hubei Province of China, No. 2014CFB645; Research and Development Project of the Science and Technology Plan of Hubei Province, No. 2011BCB030; Foundation for Innovative Research Team

of Hubei University of Medicine, No. 2014CXG05; and Key Program for Precision Medicine of Taihe Hospital, No. 2016JZ05.

Conflict-of-interest statement: The authors have no conflicts of interest associated with this manuscript.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Correspondence to: Zhong-Ji Meng, MD, Professor of Medicine, Taihe Hospital, Hubei University of Medicine, No. 32, South Renmin Road, Shiyan 442000, Hubei Province, China. zhongji.meng@taihehospital.com
Telephone: +86-719-8801821
Fax: +86-719-8801821

Received: June 7, 2017

Peer-review started: June 8, 2017

First decision: July 13, 2017

Revised: July 29, 2017

Accepted: August 15, 2017

Article in press: August 15, 2017

Published online: September 14, 2017

Abstract

AIM

To investigate the potential effect of curcumin on

hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) and the underlying mechanism.

METHODS

A HepG2.2.15 cell line stably transfected with HBV was treated with curcumin, and HBV surface antigen (HBsAg) and e antigen (HBeAg) expression levels were assessed by ELISA. Intracellular HBV DNA replication intermediates and cccDNA were detected by Southern blot and real-time PCR, respectively. The acetylation levels of histones H3 and H4 were measured by Western blot. H3/H4-bound cccDNA was detected by chromatin immunoprecipitation (ChIP) assays. The deacetylase inhibitors trichostatin A and sodium butyrate were used to study the mechanism of action for curcumin. Additionally, short interfering RNAs (siRNAs) targeting HBV were tested along with curcumin.

RESULTS

Curcumin treatment led to time- and dose-dependent reductions in HBsAg and HBeAg expression and significant reductions in intracellular HBV DNA replication intermediates and HBV cccDNA. After treatment with 20 $\mu\text{mol/L}$ curcumin for 2 d, HBsAg and cccDNA levels in HepG2.2.15 cells were reduced by up to 57.7% ($P < 0.01$) and 75.5% ($P < 0.01$), respectively, compared with levels in non-treated cells. Meanwhile, time- and dose-dependent reductions in the histone H3 acetylation levels were also detected upon treatment with curcumin, accompanied by reductions in H3- and H4-bound cccDNA. Furthermore, the deacetylase inhibitors trichostatin A and sodium butyrate could block the effects of curcumin. Additionally, transfection of siRNAs targeting HBV enhanced the inhibitory effects of curcumin.

CONCLUSION

Curcumin inhibits HBV gene replication *via* down-regulation of cccDNA-bound histone acetylation and has the potential to be developed as a cccDNA-targeting antiviral agent for hepatitis B.

Key words: Curcumin; Hepatitis B virus; Covalently closed circular DNA; Histone deacetylation

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: We showed that curcumin inhibited hepatitis B virus (HBV) replication and expression *via* reductions in covalently closed circular DNA-bound histone acetylation. Furthermore, siRNAs targeting HBV acted synergistically with curcumin, resulting in enhanced inhibition of HBV.

Wei ZQ, Zhang YH, Ke CZ, Chen HX, Ren P, He YL, Hu P, Ma DQ, Luo J, Meng ZJ. Curcumin inhibits hepatitis B virus infection by down-regulating cccDNA-bound histone acetylation. *World J Gastroenterol* 2017; 23(34): 6252-6260 Available from:

URL: <http://www.wjgnet.com/1007-9327/full/v23/i34/6252.htm>
DOI: <http://dx.doi.org/10.3748/wjg.v23.i34.6252>

INTRODUCTION

Hepatitis B virus (HBV) is a species of the genus *Orthohepadnavirus*. HBV infection leads to severe diseases, including hepatitis, liver cirrhosis and hepatocellular carcinoma^[1]. HBV has also been suggested to be involved in the development of pancreatic cancer^[2]. Approximately 350 million individuals are infected with HBV, and more than 0.6 million people with HBV infection die every year as a result of end-stage liver disease and hepatocellular carcinoma worldwide^[1,3]. The HBV genome is made of partially double-stranded relaxed circular DNA (rcDNA), 3020-3320 bp in size^[4]. After the virus infects hepatocytes, rcDNA is released into the nucleus and converted to covalently closed circular DNA (cccDNA), which, along with histone binding, constitutes a minichromosome. The mean copies of cccDNA per HBV-infected hepatocyte range from 5 to 50^[5,6]. Moreover, cccDNA serves as the critical template for viral replication and mRNA synthesis, which is the source of persistent and recurrent HBV infection. Nucleos(t)ide analogues (NAs) can efficiently inhibit HBV replication; however, they do not promote clearance of residual cccDNA^[7].

Several treatment strategies are available to target cccDNA by inhibiting cccDNA minichromosome formation or inducing cccDNA degradation. Disubstituted sulfonamide (DSS) compounds have been reported to be specific inhibitors that prevent rcDNA conversion into cccDNA; however, DSS cannot promote cccDNA decay^[8]. Lucifora *et al*^[9] showed that inducing apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3A (APOBEC3A) and 3B (APOBEC3B) cytidine deaminase by interferon- α and lymphotoxin- β receptor activation induces cccDNA degradation *via* cytidine deamination and apurinic/apyrimidinic site formation. However, the absence of specificity of these cytidine deaminases results in genomic damage and cell-cycle arrest^[10]. Recently, with the aid of DNA-cleaving enzymes, including zinc-finger nucleases (ZFN), TAL effector nucleases (TALENs), and CRISPR-associated system 9 (Cas9) proteins, specific targeting of HBV cccDNA was shown to cleave cccDNA^[11-15]. Nevertheless, chronic expression of enzymes leads to off-target cleavage at homologous sequences in the human genome and represents a major limitation.

Furthermore, cccDNA-bound acetylated histones can modulate HBV replication and expression^[16,17]. Hepatitis B virus X (HBx) protein can be recruited onto a cccDNA minichromosome to accelerate acetylation. Using a cccDNA chromatin immunoprecipitation (ChIP)-Seq assay, Tropberger *et al*^[18] reported that low levels of histone posttranslational modifications (PTMs)

were associated with transcriptional repression and promoter silencing.

Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione] was isolated from the rhizome of *Curcuma longa* L. (Zingiberaceae family), which exhibits antimicrobial activities against various bacteria, viruses, fungi, and parasites^[19-23]. Curcumin can inhibit HBV *via* down-regulation of the gluconeogenesis gene coactivator PGC-1 α ^[24] or trans-activation of transcription and increased stability of p53^[25].

Based on findings that curcumin can inhibit p300 histone acetyltransferase activity^[26,27], we hypothesized that deacetylation of cccDNA-bound histones may contribute to the inhibitory activities of curcumin on HBV. Therefore, the effects of curcumin on cccDNA-bound histones and on steady-state levels of HBV cccDNA were investigated in detail in the present study.

MATERIALS AND METHODS

Cell culture and transfection

HepG2.2.15 cells (an HBV stably transfected human hepatocarcinoma cell line) were maintained in DMEM medium (Gibco, Carlsbad, CA, United States) supplemented with 10% foetal bovine serum (Gibco), 1% GlutaMAX-I (Gibco) and 1% MEM Non-Essential Amino Acids Solution (Gibco). Transfection of siRNAs into HepG2.2.15 cells was performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, United States). The sequences were 5'-GAAUCCUCACAAUACCGCAtt and 5'-UGAGAGUCCAAGAGUCCUctt for HBx-siRNA and 5'-GAAUCCUCACAAUACCGCAtt and 5'-UGCGGUAAUUGAGGAUUCtt for hepatitis B virus S antigen (HBs)-siRNA^[28].

Curcumin and deacetylase inhibitor treatments

Cells were seeded at approximately 60%-80% confluence 24 h prior to treatment with different concentrations of curcumin (Sigma, St. Louis, MO, United States) dissolved in dimethyl sulphoxide (DMSO). For histone acetylation blocking assays, cells were co-treated with 20 μ mol/L curcumin and either 5 mmol/L sodium butyrate (Sigma) or 1 μ mol/L trichostatin A (TSA, Sigma).

Nucleoprotein extraction and Western blot analysis

Nucleoproteins were extracted using a Nucleoprotein Extraction Kit (Sangon Biotech, Shanghai, China) according to the manufacturer's instructions. For Western blot analysis, proteins were subjected to SDS-polyacrylamide gel electrophoresis on 12.5% gels and were then electrophoretically transferred to nitrocellulose membranes (Millipore, Billerica, MA, United States). The membranes were blocked with 5% non-fat milk in Tris-buffered saline (TBS; pH 7.5) with 0.05% Tween 20 for 2 h at RT and were then probed with rabbit polyclonal anti-acetyl-histone H3

(Abnova, diluted 1:1000) overnight at 4 °C. Mouse monoclonal anti-histone H3 (Beyotime Biotechnology, diluted 1:1000) served as an internal control protein. Horseradish peroxidase-conjugated goat anti-mouse antibody (Biosharp, 1:5000) was used as a secondary antibody. Protein bands were visualized by enhanced chemiluminescence (ECL) using an ECL kit (Millipore).

Extraction and quantification of HBV cccDNA

HepG2.2.15 cells were lysed in 800 μ L of lysis buffer [50 mmol/L Tris-HCl (pH 8.0), 10 mmol/L EDTA, 150 mmol/L NaCl and 1% SDS] and incubated for 30 min at 4 °C. Cell lysates were adjusted to 0.5 mol/L KCl and centrifuged for 1 min at 10000 *g* to precipitate protein-bound DNA. Supernatants were digested with 0.5 mg/mL proteinase K for 2 h at 55 °C. The cccDNA was purified by phenol/chloroform (1:1) extraction and isopropanol precipitation in the presence of 15 μ g of tRNA and 200 mM NaAc (pH 5.2).

Purified DNA was digested with Plasmid-Safe ATP-Dependent DNase (Epicenter, Madison, WI, United States) to degrade contaminating HBV inserted in cellular genomic DNA and OC (open circular) species and was then subjected to PCR amplification to select HBV cccDNA forms, as previously described^[15]. The cccDNA was later subjected to real-time-PCR using SYBR Green Real-time PCR Master Mix (Roche, Mannheim, Germany) and cccDNA-specific primers: 5'-TGCACTTCGCTTCACCT (forward) and 5'-AGGGGCATTGGTGGTC (reverse). PCR was performed using an Applied Biosystems StepOne Real-Time PCR System. cccDNA copy numbers were quantified according to a standard curve generated from an HBV plasmid in a concentration range of 10²-10⁸ copies.

Extraction and quantification of HBV mRNA

Total RNA was extracted from HepG2.2.15 cells using TRIzol Reagent (Invitrogen) according to the manufacturer's instructions and was then subjected to real-time-PCR using primers for cccDNA quantification; β -actin mRNA transcript levels were used to normalize the expression of each RNA sample.

cccDNA acetyl-histone H3 and acetyl-histone H4 ChIP assays

cccDNA ChIP assays were performed using EpiQuik Acetyl-Histone H3 ChIP and EpiQuik Acetyl-Histone H4 ChIP kits (EpiGentek, Farmingdale, NY, United States). Briefly, cells were collected and *in vivo* cross-linked in fresh culture medium containing 1% formaldehyde for 10 min at RT and were then lysed in 200 μ L CP3A for 10 min at RT to isolate nuclear pellets. Chromatin solutions were sonicated for 4 pulses of 12 s each at level 5 using a Branson Microtip probe, followed by a 40-s rest on ice between each pulse to generate 200- to 1000-bp DNA fragments. Supernatants were diluted with CP4 at a 1:1 ratio, and 5 μ L was removed as "input DNA". Chromatin was then subjected to




Figure 1 Cell cytotoxicity of curcumin. HepG2.2.15 cells were treated with 0, 5, 10, 15, 20 or 30 μmol/L curcumin for 2 d and then subjected to CCK-8 assay to detect toxic effect. The experiment was performed in duplicate and repeated at least three times.

immunoprecipitation for 1 h at RT using strip wells pre-coated with antibodies specific to acetyl-histone H3, acetyl-histone H4 or normal mouse IgG. After six washes with CP1, immunoprecipitated chromatin and input DNA coated on the strip wells were digested with proteinase K and then purified using collection tubes. Purified DNA was subjected to Plasmid-Safe ATP-Dependent DNase digestion and real-time PCR amplification, as described above.

Quantification of HBV antigens

Culture supernatants of HepG2.2.15 cells were harvested and analysed for HBV surface antigen (HBsAg) and e antigen (HBeAg) levels using a Thermo Scientific Multiskan FC Microplate Photometer and ELISA kits (InTec, Xiamen, China).

Purification of HBV DNA from intracellular core particles and Southern blot analysis

HepG2.2.15 cells were washed twice with ice-cold PBS and lysed in 800 μL of lysis buffer [50 mmol/L Tris-HCl (pH 7.4), 1 mmol/L EDTA and 1% NP-40]. Cell lysates were centrifuged for 1 min at 10000 *g* to precipitate cell nuclei. Cellular genomic DNA and cccDNA were removed by the addition of 10 mM MgCl₂ and 100 μg/mL DNase I, and the mixture was incubated for 30 min at 37 °C. Digestion was stopped by the addition of 25 mmol/L EDTA (pH 8.0). Proteins were digested with 0.5 mg/mL proteinase K and 1% SDS for 2 h at 55 °C. HBV DNA from intracellular core particles was purified by phenol/chloroform (1:1) extraction and isopropanol precipitation in the presence of 15 μg of tRNA and 200 mmol/L NaAc (pH 5.2)^[28,29].

For Southern blot analysis, HBV DNA was subjected to agarose gel electrophoresis, followed by denaturation and transfer to nylon membranes using a Model 785 Vacuum Blotter (Bio-Rad, Hercules, CA, United States). DNA was fixed to membranes using an Ultraviolet Crosslinker (UVP, Upland, CA, United States). DNA hybridization and detection were performed using the DIG High Prime DNA Labelling and Detection Starter Kit

II (Roche).

Statistical analysis

Statistical analyses were performed using unpaired *t*-tests. The results were evaluated with GraphPad Prism 5 and are expressed as the mean ± SD. *P* values < 0.05 (a) or < 0.01 (b) were set as the level of significance.

RESULTS

Curcumin inhibits HBV replication and expression

To confirm whether curcumin directly inhibits HBV expression, HepG2.2.15 cells were treated with various concentrations of curcumin for three consecutive days. Cell cytotoxicity was assessed using the CCK-8 assay, which revealed that there was no detectable toxic effect when cells were treated with less than 20 μmol/L curcumin (Figure 1). Cell culture supernatants from each day were collected and analysed for levels of HBsAg and HBeAg. Curcumin decreased HBsAg levels both dose- and time-dependently; HBsAg levels were reduced by up to 57.7%, 2 d after treatment with 20 μmol/L curcumin (Figure 2A). HBeAg was not reduced by 20 μmol/L of curcumin (Figure 2B). HBV cccDNA and HBV DNA from intracellular core particles were assayed 2 d after treatment with 20 μmol/L curcumin. RT-PCR and Southern blot experiments revealed strong reductions in cccDNA (75.5%; Figure 2C), mRNA (24.4%; Figure 2D) and HBV replication intermediates (Figure 2E).

Curcumin mediates the deacetylation of chromosomal and cccDNA-bound histones

To investigate the effects of curcumin on chromosomal histone acetylation, equivalent numbers of HepG2.2.15 cells were treated with various concentrations of curcumin for 2 d or with 20 μmol/L curcumin for different durations. As shown in Figure 3A and B, curcumin decreased histone acetylation levels both dose- and time-dependently. We found that 5 μmol/L curcumin was sufficient to decrease histone acetylation. When cells were treated with 20 μmol/L curcumin, acetylated histone H3 was reduced 30 min after treatment. Using a cccDNA ChIP assay, we found that the acetylation levels of cccDNA-bound histone H3 and histone H4 were significantly reduced when cells were treated with 20 μmol/L curcumin (Figure 3C). This finding is similar to our observed reduction of chromosomal histone acetylation.

Histone deacetylase inhibitors block the inhibitory effect of curcumin

The histone deacetylase inhibitors sodium butyrate and TSA were used to test whether curcumin inhibits HBV by decreasing histone acetylation. HepG2.2.15 cells were treated with 20 μmol/L curcumin for 2 d, which resulted in significant reductions in the




Figure 2 Curcumin inhibits hepatitis B virus replication and expression. A: HepG2.215 cells were treated with 0, 5, 10, 15, 20 or 30 $\mu\text{mol/L}$ curcumin for three consecutive days. Culture medium from each day was collected and analysed for levels of HBsAg; B: Culture medium from each day was collected and analysed for levels of HBeAg; C: Hepatitis B virus (HBV) cccDNA accumulation in HepG2.215 cells treated with 20 $\mu\text{mol/L}$ curcumin or DMSO for 2 d. HBV cccDNA was digested with Plasmid-Safe ATP-Dependent DNase to degrade contaminating HBV that had inserted in cellular genomic DNA and OC species and was then subjected to PCR amplification to amplify HBV cccDNA forms. Results are expressed as numbers of cccDNA copies per cell; D: Total RNA was extracted from HepG2.215 cells treated with 20 $\mu\text{mol/L}$ curcumin or DMSO for 2 d and was subjected to real-time PCR to quantify HBV mRNA transcript levels; E: HBV DNA was extracted from intracellular core particles in HepG2.215 cells treated with 20 $\mu\text{mol/L}$ curcumin or DMSO for 2 d. Southern blot analysis of HBV DNA replicative intermediates. RC, DL and SS represent relaxed circular, double linear and single-stranded forms of HBV DNA, respectively. All experiments were repeated at least three times; ELISA and RT-PCR were performed in duplicate. ^a $P < 0.05$; ^b $P < 0.01$. cccDNA: Covalently closed circular DNA; DMSO: Dimethyl sulphoxide.

levels of HBsAg (Figure 4A) and cccDNA (Figure 4B). HBsAg and cccDNA levels increased by 31.3% and 2.4-fold, respectively, when cells were co-treated with curcumin and sodium butyrate compared with cells treated with curcumin alone. The histone deacetylase inhibitor TSA also partially blocked the inhibitory effect of curcumin on HBV, although the effect was much weaker than that of sodium butyrate. These findings suggest that curcumin inhibits HBV by inducing histone

deacetylation.

siRNAs against HBV enhance the inhibitory effects of curcumin

Because HBx also regulates epigenetic modifications of cccDNA-bound histones^[16], HBx-siRNA and HBs-siRNA were used to enhance the inhibitory effects of curcumin. HepG2.2.15 cells were transfected with 20 nmol/L siRNAs and treated with 20 $\mu\text{mol/L}$ curcumin




Figure 3 Curcumin mediates chromosomal and covalently closed circular DNA-bound histone deacetylation. A: HepG2.215 cells were treated with 0, 1, 2.5, 5 or 10 $\mu\text{mol/L}$ curcumin and incubated at 37 $^{\circ}\text{C}$ for 2 d. The acetylation status of cellular H3 histones was analysed by Western blot; B: HepG2.215 cells were treated with 20 $\mu\text{mol/L}$ curcumin for the indicated periods of time; C: ChIP on HepG2.215 cells treated with 20 $\mu\text{mol/L}$ curcumin or DMSO for 2 d was performed using specific antibodies to acetyl-histone H3 (AcH3), acetyl-histone H4 (AcH4) or control IgG. Immunoprecipitated chromatin was digested with Plasmid-Safe ATP-Dependent DNase to degrade contaminating HBV that had inserted in cellular genomic DNA and OC species and then were subjected to PCR amplification to select HBV cccDNA forms. All experiments were repeated at least three times. cccDNA: Covalently closed circular DNA; HBV: Hepatitis B virus; DMSO: Dimethyl sulphoxide.




Figure 4 Histone deacetylase inhibitors block the inhibitory effect of curcumin. A: HepG2.215 cells were treated with 20 $\mu\text{mol/L}$ curcumin alone or with either 5 mmol/L sodium butyrate or 1 $\mu\text{mol/L}$ TSA for 2 d. Medium was collected and analysed for levels of HBsAg; B: HBV cccDNA was extracted and subjected to real-time qPCR. All experiments were performed in duplicate and repeated at least three times. $^{\text{a}}P < 0.05$; $^{\text{b}}P < 0.01$. cccDNA: Covalently closed circular DNA; DMSO: Dimethyl sulphoxide; TSA: Trichostatin A; HBV: Hepatitis B virus; HBsAg: HBV surface antigen.

for 2 subsequent days. Transfection with siRNAs alone significantly reduced HBsAg expression to a level below the limit of detection (Figure 5A). Moreover, a further reduction was observed in HBV DNA levels from intracellular core particles extracted from cells that received combined treatment with siRNAs and curcumin compared with cells treated with curcumin alone (Figure 5B).

DISCUSSION

The present study showed that curcumin not only inhibited intracellular HBV replication and HBsAg and HBeAg expression but also exhibited potent inhibitory effects on HBV cccDNA. Moreover, curcumin also reduced levels of both chromosomal and cccDNA-bound histones H3/H4, and addition of the histone deacetylase inhibitors sodium butyrate and TSA blocked the inhibitory effects of curcumin on HBV. These findings suggest that curcumin may induce the deacetylation of cccDNA-bound histones H3/H4, disrupt the steady state of HBV cccDNA and lead to the potent inhibition of HBV mRNA transcription and protein expression, along with a reduction in DNA replication. Furthermore, enhanced inhibition of intracellular HBV replication was revealed when curcumin was

combined with siRNAs against HBV. Since HBx is pivotal for the steady state of cccDNA by regulating epigenetic modifiers of cccDNA-bound histones^[16,30], the combination of curcumin with siRNAs, especially those targeting HBx, may lead to a synergistic effect in modulating the cccDNA steady state.

Several host-related factors, including histone proteins, regulate transcription and translation processes of cccDNA minichromosomes. Acetylation status changes of cccDNA-bound histones can regulate cccDNA transcription^[16]. Previous studies have indicated that acetyltransferase inhibitors and deacetylase activators inhibit cccDNA transcription^[16,31]. Curcumin has been reported to be an inhibitor of histone acetyltransferase (HAT), which specifically represses the activity of the p300/CREB-binding protein (CBP) HAT^[26,27]. In the present study, curcumin mediated reductions in the levels of chromosomal and cccDNA-bound histone acetylation, which might result from the induction of histone deacetylation, because the deacetylase inhibitors TSA and sodium butyrate could block the inhibitory effects of curcumin on HBV.

HBV cccDNA is the primary template that allows for HBV gene expression and viral replication, and the steady state of cccDNA minichromosomes in the nuclei of hepatocytes contributes to persistent infection by




Figure 5 siRNAs against hepatitis B virus enhance the inhibitory effects of curcumin. HepG2.215 cells were transfected with 20 nmol/L siRNAs or negative control (HC) siRNA and were treated with 20 μ mol/L curcumin or dimethyl sulphoxide for the next 2 d. HBsAg in cell culture supernatants and intracellular HBV replicative intermediates were detected by ELISA (A) and Southern blot analysis (B), respectively. All experiments were repeated at least three times; ELISA was performed in duplicate. ^a $P < 0.05$; ^b $P < 0.01$. HBV: Hepatitis B virus; HBsAg: HBV surface antigen.

HBV^[32]. While there are no therapeutics currently available that target cccDNA, targeted therapeutics are attractive because the elimination of cccDNA results in the genomic cure of HBV infection^[5]. Although genomic editing techniques, such as the CRISPR/CAS9 system, have shown promise in their capacity to edit HBV cccDNA, translating this finding into the clinic will be a challenge, mostly because of the need for the development of safe vectors for gene therapies.

Curcumin has been widely used as a dietary supplement for food colouring and flavouring, suggesting that it is safe for humans. However, poor bioavailability represents the biggest challenge for the clinical application of curcumin^[33]. Poor absorption and rapid metabolism of curcumin in the body lead to low levels in the plasma and tissue. Fortunately, various efforts have been undertaken to promote its bioavailability. Removing the β -diketone moiety prevents curcumin from retro-aldol decomposition at physiological pH values^[34]. Curcumin conjugated to two folic acid molecules (curcumin-2FA) increases water solubility and exhibits more efficient targeting of cancer cells that overexpress folic acid receptors^[35]. Additionally, many other curcumin analogues can improve its bioavailability^[36-40]. Moreover, curcumin-modified silver nanoparticles exhibited more efficient inhibition of respiratory syncytial virus^[21]. Improving

the bioavailability of curcumin will extend its clinical applications, especially in the treatment of HBV infection. Nevertheless, the long-term effects of curcumin on HBV cccDNA and its role in the elimination of cccDNA, along with combined effects of curcumin with other therapeutics, should be investigated in detail.

Taken together, the present study demonstrates that curcumin inhibits HBV by reducing cccDNA-bound histone acetylation and could potentially be developed as a cccDNA-targeting therapeutic for anti-HBV therapy.

COMMENTS

Background

Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) is the critical template for viral replication and mRNA synthesis. The elimination of cccDNA is indicative of complete cure of hepatitis B. Nucleos(t)ide analogues (NAs) can efficiently inhibit HBV replication but do not result in clearance of residual cccDNA. Curcumin can inhibit HBV; however, its mechanism is unclear. The potential role of curcumin in the regulation of the steady state of cccDNA is thus of interest.

Research frontiers

The steady state of cccDNA minichromosomes can be regulated through deacetylation of cccDNA-bound histones. Hepatitis B virus X (HBx) protein is recruited onto cccDNA minichromosomes and plays a pivotal role in the steady state of cccDNA by regulating epigenetic modifiers of cccDNA-bound histones.

Innovations and breakthroughs

This is the first study indicating that curcumin inhibits HBV gene replication by reducing cccDNA-bound histone acetylation.

Applications

Curcumin has the potential to be developed as a cccDNA-targeting antiviral agent for hepatitis B.

Terminology

HBV covalently closed circular DNA (cccDNA): After the HBV infects hepatocytes, virus genome is released into the nucleus and converted to cccDNA, which, along with histone binding, constitutes a minichromosome and serves as the critical template for viral replication and mRNA synthesis.

Peer-review

The authors have evaluated the effects of curcumin on HBV DNA replication and gene expression in the HepG2.2.15 cell line. Interestingly, curcumin showed robust inhibitory effects on HBV cccDNA. In addition, the authors have described the mechanism underlying the effect of curcumin on HBV cccDNA, which might be through histone deacetylation or reducing histone acetylation.

REFERENCES

- 1 Fourati S, Pawlotsky JM. Recent advances in understanding and diagnosing hepatitis B virus infection. *F1000Res* 2016; **5**: pii: F1000 [PMID: 27635243 DOI: 10.12688/f1000research.8983.1]
- 2 Hassan MM, Li D, El-Deeb AS, Wolff RA, Bondy ML, Davila M, Abbruzzese JL. Association between hepatitis B virus and pancreatic cancer. *J Clin Oncol* 2008; **26**: 4557-4562 [PMID: 18824707 DOI: 10.1200/JCO.2008.17.3526]
- 3 Kim DH, Kang HS, Kim KH. Roles of hepatocyte nuclear factors in hepatitis B virus infection. *World J Gastroenterol* 2016; **22**: 7017-7029 [PMID: 27610013 DOI: 10.3748/wjg.v22.i31.7017]
- 4 Kay A, Zoulim F. Hepatitis B virus genetic variability and evolution. *Virus Res* 2007; **127**: 164-176 [PMID: 17383765 DOI: 10.1016/j.virusres.2007.02.021]

- 5 **Nassal M.** HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. *Gut* 2015; **64**: 1972-1984 [PMID: 26048673 DOI: 10.1136/gutjnl-2015-309809]
- 6 **Taranta A,** Tien Sy B, Zacher BJ, Rogalska-Taranta M, Manns MP, Bock CT, Wursthorn K. Hepatitis B virus DNA quantification with the three-in-one (3io) method allows accurate single-step differentiation of total HBV DNA and cccDNA in biopsy-size liver samples. *J Clin Virol* 2014; **60**: 354-360 [PMID: 24890819 DOI: 10.1016/j.jcv.2014.04.015]
- 7 **You CR,** Lee SW, Jang JW, Yoon SK. Update on hepatitis B virus infection. *World J Gastroenterol* 2014; **20**: 13293-13305 [PMID: 25309066 DOI: 10.3748/wjg.v20.i37.13293]
- 8 **Cai D,** Mills C, Yu W, Yan R, Aldrich CE, Saputelli JR, Mason WS, Xu X, Guo JT, Block TM, Cuconati A, Guo H. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. *Antimicrob Agents Chemother* 2012; **56**: 4277-4288 [PMID: 22644022 DOI: 10.1128/AAC.00473-12]
- 9 **Lucifora J,** Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou WM, Thasler WE, Hüser N, Durantel D, Liang TJ, Münk C, Heim MH, Browning JL, Dejardin E, Dandri M, Schindler M, Heikenwalder M, Protzer U. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. *Science* 2014; **343**: 1221-1228 [PMID: 24557838 DOI: 10.1126/science.1243462]
- 10 **Landry S,** Narvaiza I, Linfesty DC, Weitzman MD. APOBEC3A can activate the DNA damage response and cause cell-cycle arrest. *EMBO Rep* 2011; **12**: 444-450 [PMID: 21460793 DOI: 10.1038/embor.2011.46]
- 11 **Cradick TJ,** Keck K, Bradshaw S, Jamieson AC, McCaffrey AP. Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. *Mol Ther* 2010; **18**: 947-954 [PMID: 20160705 DOI: 10.1038/mt.2010.20]
- 12 **Chen J,** Zhang W, Lin J, Wang F, Wu M, Chen C, Zheng Y, Peng X, Li J, Yuan Z. An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases. *Mol Ther* 2014; **22**: 303-311 [PMID: 24025750 DOI: 10.1038/mt.2013.212]
- 13 **Lin SR,** Yang HC, Kuo YT, Liu CJ, Yang TY, Sung KC, Lin YY, Wang HY, Wang CC, Shen YC, Wu FY, Kao JH, Chen DS, Chen PJ. The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. *Mol Ther Nucleic Acids* 2014; **3**: e186 [PMID: 25137139 DOI: 10.1038/mtna.2014.38]
- 14 **Seeger C,** Sohn JA. Targeting Hepatitis B Virus With CRISPR/Cas9. *Mol Ther Nucleic Acids* 2014; **3**: e216 [PMID: 25514649 DOI: 10.1038/mtna.2014.68]
- 15 **Ramanan V,** Shlomai A, Cox DB, Schwartz RE, Michailidis E, Bhatta A, Scott DA, Zhang F, Rice CM, Bhatia SN. CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. *Sci Rep* 2015; **5**: 10833 [PMID: 26035283 DOI: 10.1038/srep10833]
- 16 **Belloni L,** Pollicino T, De Nicola F, Guerrieri F, Raffa G, Fanciulli M, Raimondo G, Levvero M. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. *Proc Natl Acad Sci USA* 2009; **106**: 19975-19979 [PMID: 19906987 DOI: 10.1073/pnas.0908365106]
- 17 **Lee JY,** Kim NA, Sanford A, Sullivan KE. Histone acetylation and chromatin conformation are regulated separately at the TNF-alpha promoter in monocytes and macrophages. *J Leukoc Biol* 2003; **73**: 862-871 [PMID: 12773519]
- 18 **Tropberger P,** Mercier A, Robinson M, Zhong W, Ganem DE, Holdorf M. Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation. *Proc Natl Acad Sci USA* 2015; **112**: E5715-E5724 [PMID: 26438841 DOI: 10.1073/pnas.1518090112]
- 19 **Moghadamtousi SZ,** Kadir HA, Hassandarvish P, Tajik H, Abubakar S, Zandi K. A review on antibacterial, antiviral, and antifungal activity of curcumin. *Biomed Res Int* 2014; **2014**: 186864 [PMID: 24877064 DOI: 10.1155/2014/186864]
- 20 **Ali A,** Banerjee AC. Curcumin inhibits HIV-1 by promoting Tat protein degradation. *Sci Rep* 2016; **6**: 27539 [PMID: 27283735 DOI: 10.1038/srep27539]
- 21 **Yang XX,** Li CM, Huang CZ. Curcumin modified silver nanoparticles for highly efficient inhibition of respiratory syncytial virus infection. *Nanoscale* 2016; **8**: 3040-3048 [PMID: 26781043 DOI: 10.1039/c5nr07918g]
- 22 **Pêcheur EI.** Curcumin against hepatitis C virus infection: spicing up antiviral therapies with 'nutraceuticals'? *Gut* 2014; **63**: 1035-1037 [PMID: 24092864 DOI: 10.1136/gutjnl-2013-305646]
- 23 **Anggakusuma,** Colpitts CC, Schang LM, Rachmawati H, Frentzen A, Pfaender S, Behrendt P, Brown RJ, Bankwitz D, Steinmann J, Ott M, Meuleman P, Rice CM, Ploss A, Pietschmann T, Steinmann E. Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. *Gut* 2014; **63**: 1137-1149 [PMID: 23903236 DOI: 10.1136/gutjnl-2012-304299]
- 24 **Rechtman MM,** Har-Noy O, Bar-Yishay I, Fishman S, Adamovich Y, Shaul Y, Halpern Z, Shlomai A. Curcumin inhibits hepatitis B virus via down-regulation of the metabolic coactivator PGC-1alpha. *FEBS Lett* 2010; **584**: 2485-2490 [PMID: 20434445 DOI: 10.1016/j.febslet.2010.04.067]
- 25 **Kim HJ,** Yoo HS, Kim JC, Park CS, Choi MS, Kim M, Choi H, Min JS, Kim YS, Yoon SW, Ahn JK. Antiviral effect of Curcuma longa Linn extract against hepatitis B virus replication. *J Ethnopharmacol* 2009; **124**: 189-196 [PMID: 19409970 DOI: 10.1016/j.jep.2009.04.046]
- 26 **Zhu X,** Li Q, Chang R, Yang D, Song Z, Guo Q, Huang C. Curcumin alleviates neuropathic pain by inhibiting p300/CBP histone acetyltransferase activity-regulated expression of BDNF and cox-2 in a rat model. *PLoS One* 2014; **9**: e91303 [PMID: 24603592 DOI: 10.1371/journal.pone.0091303]
- 27 **Balasubramanyam K,** Varier RA, Altaf M, Swaminathan V, Siddappa NB, Ranga U, Kundu TK. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. *J Biol Chem* 2004; **279**: 51163-51171 [PMID: 15383533 DOI: 10.1074/jbc.M409024200]
- 28 **Meng Z,** Xu Y, Wu J, Tian Y, Kemper T, Bleekmann B, Roggendorf M, Yang D, Lu M. Inhibition of hepatitis B virus gene expression and replication by endoribonuclease-prepared siRNA. *J Virol Methods* 2008; **150**: 27-33 [PMID: 18378325 DOI: 10.1016/j.jviromet.2008.02.008]
- 29 **Meng Z,** Qiu S, Zhang X, Wu J, Schreiter T, Xu Y, Yang D, Roggendorf M, Schlaak J, Lu M. Inhibition of woodchuck hepatitis virus gene expression in primary hepatocytes by siRNA enhances the cellular gene expression. *Virology* 2009; **384**: 88-96 [PMID: 19064272 DOI: 10.1016/j.virol.2008.11.012]
- 30 **Rivière L,** Gerossier L, Ducroux A, Dion S, Deng Q, Michel ML, Buendia MA, Hantz O, Neuveut C. HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase. *J Hepatol* 2015; **63**: 1093-1102 [PMID: 26143443 DOI: 10.1016/j.jhep.2015.06.023]
- 31 **Pollicino T,** Belloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G, Levvero M. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. *Gastroenterology* 2006; **130**: 823-837 [PMID: 16530522 DOI: 10.1053/j.gastro.2006.01.001]
- 32 **Guidotti LG,** Isogawa M, Chisari FV. Host-virus interactions in hepatitis B virus infection. *Curr Opin Immunol* 2015; **36**: 61-66 [PMID: 26186123 DOI: 10.1016/j.coi.2015.06.016]
- 33 **Anand P,** Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. *Mol Pharm* 2007; **4**: 807-818 [PMID: 17999464 DOI: 10.1021/mp700113r]
- 34 **Kumari N,** Kulkarni AA, Lin X, McLean C, Ammosova T, Ivanov A, Hipolito M, Nekhai S, Nwulia E. Inhibition of HIV-1 by curcumin A, a novel curcumin analog. *Drug Des Devel Ther* 2015; **9**: 5051-5060 [PMID: 26366056 DOI: 10.2147/DDDT.S86558]
- 35 **Mishra A,** Das BC. Curcumin as an anti-human papillomavirus and anti-cancer compound. *Future Oncol* 2015; **11**: 2487-2490 [PMID: 26278542 DOI: 10.2217/fon.15.166]
- 36 **Bharitkar YP,** Das M, Kumari N, Kumari MP, Hazra A, Bhayye

- SS, Natarajan R, Shah S, Chatterjee S, Mondal NB. Synthesis of Bis-pyrrolizidine-Fused Dispiro-oxindole Analogues of Curcumin via One-Pot Azomethine Ylide Cycloaddition: Experimental and Computational Approach toward Regio- and Diastereoselection. *Org Lett* 2015; **17**: 4440-4443 [PMID: 26331906 DOI: 10.1021/acs.orglett.5b02085]
- 37 **Ahsan N**, Mishra S, Jain MK, Surolia A, Gupta S. Curcumin Pyrazole and its derivative (N-(3-Nitrophenyl)pyrazole) Curcumin inhibit aggregation, disrupt fibrils and modulate toxicity of Wild type and Mutant α -Synuclein. *Sci Rep* 2015; **5**: 9862 [PMID: 25985292 DOI: 10.1038/srep09862]
- 38 **Gogoi B**, Sen Sarma N. Curcumin-cysteine and curcumin-tryptophan conjugate as fluorescence turn on sensors for picric Acid in aqueous media. *ACS Appl Mater Interfaces* 2015; **7**: 11195-11202 [PMID: 25955402 DOI: 10.1021/acsami.5b01102]
- 39 **Pan Y**, Wang Y, Cai L, Cai Y, Hu J, Yu C, Li J, Feng Z, Yang S, Li X, Liang G. Inhibition of high glucose-induced inflammatory response and macrophage infiltration by a novel curcumin derivative prevents renal injury in diabetic rats. *Br J Pharmacol* 2012; **166**: 1169-1182 [PMID: 22242942 DOI: 10.1111/j.1476-5381.2012.01854.x]
- 40 **Wang Y**, Xiao J, Zhou H, Yang S, Wu X, Jiang C, Zhao Y, Liang D, Li X, Liang G. A novel monocarbonyl analogue of curcumin, (1E,4E)-1,5-bis(2,3-dimethoxyphenyl)penta-1,4-dien-3-one, induced cancer cell H460 apoptosis via activation of endoplasmic reticulum stress signaling pathway. *J Med Chem* 2011; **54**: 3768-3778 [PMID: 21504179 DOI: 10.1021/jm200017g]
- P- Reviewer:** Farshadpour F, Inoue K, Jarcuska P, Kim K, Larrubia JR
S- Editor: Ma YJ **L- Editor:** Wang TQ **E- Editor:** Zhang FF





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgooffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>



ISSN 1007-9327

